Latest news with #CompetitiveLandscape
Globe and Mail
2 days ago
- Business
- Globe and Mail
Gene Therapy Competitive Landscape Report 2025
DelveInsight's, ' Gene Therapy Competitive landscape, 2025,' report provides comprehensive insights about 180+ companies and 200+ drugs in Gene Therapy Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Gene Therapy Treatment Landscape @ Gene Therapy Pipeline Outlook Key Takeaways from the Gene Therapy Competitive Landscape Report On 17 August 2025, MeiraGTx LLC conducted a study of individual participation in this study will be approximately 54 months for participants who received AAV-GAD in Study MGT-GAD-025 and approximately 60 months for participants who received sham surgery in Study MGT-GAD-025. On 15 August 2025, Janssen Research & Development LLC organized a Phase 3 Follow-up Study of for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene. On 13 August 2025, REGENXBIO Inc. announced a phase I/II/III study to evaluate the safety, tolerability, pharmacodynamics (microdystrophin protein levels), pharmacokinetic, and clinical efficacy of RGX-202 when administered IV as one-time dose to ambulant male participants with Duchenne. A comprehensive, short-term, prophylactic immunosuppression regimen will be administered during treatment to mitigate a potential immune response. This study is being conducted in three sequential parts: a phase I/II study (Part 1), a phase 3 pivotal study (Part 2) and a confirmatory study (Part 3). Part 1 will study a one-time dose of RGX-202 (1x10^14 or 2x10^14 GC/kg) in up to 15 participants with Duchenne. DelveInsight's Gene Therapy Competitive landscape report depicts a robust space with 180-+ active players working to develop 200+ pipeline therapies for Gene Therapy treatment. The leading Gene Therapy Companies such as Pfizer, Ultragenyx Pharmaceutical Inc, Rocket Pharmaceuticals, Adverum Biotechnologies, Kyverna Therapeutics, Vivet Therapeutics, HELIXMITH Co, Rocket Pharmaceuticals, Bristol-Myers Squibb, Wellington Zhaotai Therapies, Reyon Pharmaceutical, Neowise Biotechnology, Orna Therapeutics, Genflow Biosciences, Xylocor Therapeutics, Kolon TissueGene, Allogene Therapeutics, Nanjing IASO Biotherapeutics, Shanghai Vitalgen BioPharma, Rui Therapeutics, Obsidian Therapeutics, YolTech Therapeutics, Neurotech USA, Beacon Therapeutics, REGENXBIO and others. Promising Gene Therapy Therapies such as Tipifarnib, Sucrose (3%), Chemotherapy, UX111, SPK-8011, SBT101, Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib and others. Discover groundbreaking developments in Gene Therapy Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Gene Therapy Clinical Trials Assessment Gene Therapy Marketed Therapies Novartis Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, company use innovative science and digital technologies to create transformative treatments in areas of great medical need. In quest to find new medicines, consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally and are finding innovative ways to expand access to company latest treatments. Novartis Gene Therapies is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, company is working to turn promising gene therapies into proven treatments. Zolgensma Zolgensma (onasemnogene abeparvovec) is the only gene therapy for spinal muscular atrophy (SMA) and the only SMA treatment designed to directly address the genetic root cause of the disease by replacing the function of the missing or non-working SMN gene to halt disease progression through sustained SMN protein expression with a single, one-time IV infusion. Zolgensma was approved by the US Food and Drug Administration for the treatment of pediatric patients less than 2years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. . Zolgensma is now approved in more than 40 countries and more than 2,000 patients have been treated with Zolgensma globally across clinical trials, managed access programs, and in the commercial setting. Spark Therapeutics Spark Therapeutics, is a fully integrated company committed to discovering, developing and delivering gene therapies, challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. The company have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, there is the path to a world where no life is limited by genetic disease. LUXTURNA LUXTURNA is the first FDA-approved gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease (IRD) and the first adeno-associated virus (AAV) vector gene therapy approved in the U.S. LUXTURNA was approved by FDA under Priority Review and previously received orphan drug and breakthrough therapy designations from FDA. With the approval of LUXTURNA, FDA will issue to Spark Therapeutics a Rare Pediatric Disease Priority Review Voucher for a Priority Review of a subsequent marketing application for a different product. Spark Therapeutics' Marketing Authorization Application (MAA) for LUXTURNA is currently under review with the European Medicines Agency (EMA). LUXTURNA also has received orphan product designations from EMA. Gene Therapy Pipeline Therapies Pfizer Pfizer Inc. is a global biopharmaceutical company with a rich history dating back to 1849 when it was founded by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company is engaged in the discovery, development, manufacture, and sale of medicines and vaccines across various therapeutic areas such as vaccines, oncology, internal medicine, hospital, inflammation and immunology, and rare diseases. Pfizer's dedication to global health is evident through its extensive portfolio of medicines and vaccines that aim to enhance wellness, prevention, treatments, and cures for various diseases. The company collaborates with healthcare providers, governments, and communities worldwide to expand access to reliable and affordable healthcare services. Fordadistrogene movaparvovec Fordadistrogene movaparvovec is an investigational recombinant adeno-associated virus serotype 9 (AAV9) capsid carrying a shortened version of the human dystrophin gene (mini-dystrophin) under the control of a human muscle-specific promotor. The AAV9 capsid was chosen as the delivery mechanism because of its potential to target muscle tissue. The FDA has lifted a clinical hold on Pfizer's phase III clinical trial of its investigational gene therapy, fordadistrogene movaparvovec, in patients with Duchenne muscular dystrophy (DMD). Regulatory and ethics approvals to resume the CIFFREO Phase III ambulatory study, including the FDA's lift of its clinical hold, follow reviews of data and protocol amendments. Currently the drug is in Phase III stage of development for the treatment of Duchenne muscular dystrophy Ultragenyx Pharmaceutical Inc Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, the company apply cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America and EMEA/International – The company focus on purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. DTX401 DTX401 is an investigational AAV8 gene therapy designed to deliver stable expression and activity of G6Pase-α using a single intravenous infusion. Long term Phase I/II data demonstrate an acceptable safety profile and durability of response. All treated patients have experienced stable or improved glucose control while tapering or discontinuing oral glucose replacement therapy with cornstarch after receiving DTX401. The Phase III GlucoGene study is underway to evaluate the ability of DTX401 to reduce the use of cornstarch while maintaining or improving glucose control as well as the therapy's impact on patients' quality of life. DTX401 was granted Orphan Drug Designation in the United States, EU and United Kingdom, and Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation in the United States. DTX401 was accepted into the EMA's Priority Medicines program (PRIME), enabling more frequent interactions with the EMA and the potential for an accelerated drug has recently completed Phase III clinical trial for the treatment of patients with Glycogen storage disease type I. Rocket Pharmaceuticals Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company focused on developing first-in-class gene therapy treatment options for rare, devastating diseases. Rocket's multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. Rocket's lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. Preclinical studies of additional bone marrow-derived disorders are ongoing and target Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). Rocket's first AAV-based gene therapy program targets Danon disease, a rare neuromuscular and cardiovascular disease. RP-L102 RP-L102 is a gene therapy product containing autologous (patient-derived) hematopoietic stem cells (HSCs) that have been genetically modified with a lentiviral vector to contain a functional copy of the FANCA gene. If given early in life, RP-L102 gene therapy has the potential to serve as a preventative measure, correcting bone marrow cells before there is progression to severe bone marrow failure. RP-L102 has been granted Orphan Drug, Fast Track, and Regenerative Medicine Advanced Therapy (RMAT) designations for the treatment of Fanconi Anemia type A in the United States and Orphan Drug designation in Europe. The drug is currently in Phase II stage of development for the treatment of patients with Fanconi Anemia (FA). Adverum Biotechnologies Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with neovascular or wet age-related macular degeneration. ADVM-022 ADVM022 is being developed for the treatment of wet AMD. ADVM-022 utilizes a propriety vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette. Unlike other ophthalmic gene therapies that require a surgery to administer the gene therapy under the retina (sub-retinal approach) ADVM-022 has the advantage of being administered as a one-time IVT injection in the office and is designed to deliver long-term efficacy and reduce the burden of frequent anti-VEGF injections, optimize patient compliance, and improve vision outcomes for patients with wet AMD. The OPTIC trial is designed as a multi-center, open-label, dose-ranging, safety and efficacy trial of ADVM-022 in patients with wet AMD who have demonstrated responsiveness to anti-VEGF treatment. Patients in OPTIC are treatment experienced, and previously required frequent anti-VEGF injections to manage their wet AMD and to maintain functional vision. The drug is currently in Phase II stage of development for the treatment of patients with Wet AMD. Kyverna Therapeutics Kyverna is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. KYV-101 is advancing through clinical development across two broad areas of autoimmune disease: rheumatology and neurology, including two ongoing multi-center, open-label Phase I trials of KYV-101 in the United States and Germany for patients with lupus nephritis. Kyverna's pipeline includes next-generation chimeric antigen receptor (CAR) T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases. By advancing more than one mechanism for taming autoimmunity, Kyverna is positioned to act on its mission of transforming how autoimmune diseases are treated. KYV-101 KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate for use in B cell-driven autoimmune diseases. The CAR in KYV-101 was designed by the National Institutes of Health (NIH) to improve tolerability and tested in a 20-patient Phase I trial in oncology. Results were published by the NIH in Nature Medicine. Kyverna is currently conducting trials of KYV-101 in patients with lupus nephritis, an autoimmune disease in which more than half of patients do not achieve a complete response to current therapies and are at risk of developing kidney failure. Additional clinical trials of KYV-101 in systemic sclerosis, and myasthenia gravis are in preparation. The drug is currently in Phase I/II stage of development for the treatment of patients with Lupus nephritis. Vivet Therapeutics Vivet Therapeutics is a private, clinical-stage biotech company developing novel and long-lasting gene therapies for rare inherited metabolic conditions, including Wilson's disease. Vivet's gene therapy platform uses recombinant adeno-associated viruses (rAAVs) as vectors and has initiated two clinical programs and four pre-clinical assets to date. Its most advanced therapy is VTX-801, a novel gene therapy for Wilson's disease, with key clinical read-outs expected by the end of 2024. Vivet Therapeutics was founded in 2016 by CEO Dr Jean-Philippe Combal and CSO Dr Gloria Gonzalez-Aseguinolaza and is led by a highly experienced management team with deep expertise developing gene therapies and orphan drugs. VTX-802 VTX-802 is an AAV-based gene therapy for patients with Progressive Familial Intrahepatic Cholestasis Type 2. It delivers a codon-optimized version of the BSEP gene to the liver and is currently under preclinical testing. The drug is currently in Preclinical stage of development for the treatment of patients with Intrahepatic cholestasis. Gene Therapy Analytical Perspective by DelveInsight In-depth Commercial Assessment: Gene Therapy Collaboration Analysis by Companies The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition – deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form. Gene Therapy Competitive Landscape The report comprises of comparative assessment of Companies (by therapy, development stage, and technology). Gene Therapy Report Assessment Company Analysis Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Transform your understanding of the Gene Therapy Pipeline! See the latest progress in drug development and clinical research @ Gene Therapy Market Drivers and Barriers, and Future Perspectives Scope of the Gene Therapy Competitive Landscape Report Coverage- Global Gene Therapy Companies- Pfizer, Ultragenyx Pharmaceutical Inc, Rocket Pharmaceuticals, Adverum Biotechnologies, Kyverna Therapeutics, Vivet Therapeutics, HELIXMITH Co, Rocket Pharmaceuticals, Bristol-Myers Squibb, Wellington Zhaotai Therapies, Reyon Pharmaceutical, Neowise Biotechnology, Orna Therapeutics, Genflow Biosciences, Xylocor Therapeutics, Kolon TissueGene, Allogene Therapeutics, Nanjing IASO Biotherapeutics, Shanghai Vitalgen BioPharma, Rui Therapeutics, Obsidian Therapeutics, YolTech Therapeutics, Neurotech USA, Beacon Therapeutics, REGENXBIO and others. Gene Therapy Analytical Perspective: In-depth Commercial Assessment Gene Therapy Unmet Needs, Preclinical and Discovery Stage Products Stay Ahead in Oncology Research–Access the Full Gene Therapy Pipeline Analysis Today! @ Gene Therapy Drugs and Companies Table of Contents Introduction Executive Summary Gene Therapy: Overview Gene Therapy -Analytical Perspective: In-depth Commercial Assessment Competitive Landscape Therapeutic Assessment Gene Therapy: Company and Product Profiles (Marketed Therapies) Novartis Zolgensma Gene Therapy: Company and Product Profiles (Pipeline Therapies) Late Stage Products (Phase III) Pfizer Fordadistrogene movaparvovec Mid Stage Products (Phase II) Rocket Pharmaceuticals RP-L102 Early Stage Products (Phase I/II) Kyverna Therapeutics KYV-101 Preclinical and Discovery Stage Products Vivet Therapeutics VTX-802 Inactive Products Gene Therapy- Unmet needs Gene Therapy – Market drivers and barriers Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
01-08-2025
- Business
- Yahoo
Protein Powder Market Trends and Forecast Report 2025-2034
Discover insights into the growing Global Protein Powder Market, projected to rise from USD 24.8 billion in 2025 to USD 45.6 billion by 2034 at a 7% CAGR. Key trends include plant-based innovation, functional enhancements, and sustainable packaging. Explore regional analyses, market segmentation, and customized research options. Protein Powder Market Dublin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The "Protein Powder Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges" report has been added to Protein Powder Market is valued at USD 24.8 billion in 2025. Further, the market is expected to grow at a CAGR of 7% to reach USD 45.6 billion by 2034. The protein powder market has grown into a mainstream nutritional segment, widely consumed not only by athletes and fitness enthusiasts but also by general consumers focused on wellness, weight management, and preventive health. Protein powders, derived from sources like whey, casein, soy, pea, rice, and hemp, serve as convenient dietary supplements that support muscle repair, metabolism, satiety, and immune function. This market has been shaped by the broader shift toward active lifestyles, personalized nutrition, and clean-label preferences. Consumers are increasingly seeking protein powders that align with their specific dietary needs, such as plant-based, gluten-free, organic, or allergen-friendly growing popularity of veganism, ketogenic diets, and high-protein regimens continues to fuel innovation in product development. Moreover, the rise of e-commerce and direct-to-consumer brands has made protein powders more accessible globally. With continued emphasis on nutrition, fitness, and longevity, the protein powder market is positioned for long-term growth across multiple demographics and 2024, the protein powder market saw dynamic expansion driven by innovation in product formats, ingredients, and distribution channels. Plant-based protein powders gained significant traction, led by consumer demand for sustainable and dairy-free alternatives. Pea, brown rice, and hemp protein blends became more common as brands focused on delivering complete amino acid profiles and improved taste. Premium offerings with added functional benefits - such as digestive enzymes, probiotics, collagen, and adaptogens - became increasingly popular among health-conscious consumers. RTD (ready-to-drink) and single-serve sachets expanded the convenience factor, particularly in urban and travel year also saw a rise in protein powders tailored to specific age groups, such as seniors or children, addressing unique nutritional needs. Social media and influencer marketing continued to play a key role in shaping consumer choices and brand loyalty. Meanwhile, regulatory scrutiny around health claims and labeling accuracy led to improved transparency and standardization within the market. Supply chain challenges persisted in some regions, but most leading brands adapted through localized sourcing and digital inventory ahead into 2025 and beyond, the protein powder market is expected to evolve with greater personalization, clean-label innovation, and global reach. AI-driven nutrition platforms and diagnostic tools will increasingly guide consumers toward protein formulations that match their biological needs, activity levels, and health goals. The development of novel protein sources such as insect, algae, and lab-cultured proteins will open new frontiers, especially for environmentally conscious consumers. Packaging innovations will focus on sustainability, including compostable materials and refillable containers to reduce plastic markets in Asia-Pacific, Latin America, and the Middle East will witness rapid adoption as awareness of protein intake rises alongside disposable incomes and fitness trends. Additionally, the incorporation of protein powders into mainstream foods - like baked goods, cereals, and snacks - will diversify usage occasions and expand consumer reach. As the market becomes more competitive, brands will need to differentiate through transparency, functional formulation, and direct engagement with consumers to retain loyalty in a rapidly evolving Trends Surging demand for plant-based protein powders is driving innovation in blends that offer complete amino acid profiles with better taste and texture. Functional enhancements such as probiotics, adaptogens, and digestive enzymes are adding value to traditional protein formulations for broader wellness benefits. Personalized nutrition tools and apps are enabling consumers to choose protein powders aligned with their health data and lifestyle goals. Expansion of sustainable packaging and environmentally friendly sourcing practices is becoming a key differentiator in brand positioning. RTD formats and on-the-go sachets are catering to convenience-seeking consumers in fitness and everyday use scenarios. Market Drivers Rising health consciousness and the adoption of high-protein diets for weight management, fitness, and general wellness are fueling consistent market demand. Growth in sports nutrition, especially among casual gym-goers and amateur athletes, is expanding the consumer base for protein powder products. Increasing popularity of plant-based and allergen-friendly products is opening opportunities for alternative protein innovation. Digitalization and e-commerce growth are making protein powders more accessible, especially in developing countries with limited physical retail infrastructure. Market Challenge Product saturation, inconsistent quality standards, and misleading health claims present challenges in consumer trust, requiring greater regulation and transparency across global markets. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $24.8 Billion Forecasted Market Value (USD) by 2034 $45.6 Billion Compound Annual Growth Rate 7.0% Regions Covered Global Companies Featured NutraBio Amway Corp. Abbott Laboratories Glanbia Plc. Herbalife International of America Inc. Vitaco Health Limited ABH Pharma Inc. GSK Plc. Makers Nutrituion LLC GNC Holdings LLC Atlantic Multipower UK Limited Melaleuca Inc. Dalblads Nutrition AB BPI Sports LLC MusclePharm Corporation CytoSport Inc. NOW Foods Hilmar Ingredients Arla Foods Ingredients ADM (Archer Daniels Midland Company) HF Series Nature's Best Kerry Group NOW Foods Isopure Dymatize Nutrition Omega Protein Corporation Jarrow Formulas Optimum Nutrition Vega Market Segmentation By Type Casein Protein Whey Protein Egg Protein Soy Protein By Flavor Chocolate Cookies And Cream Vanilla Strawberry Other Flavors By Sources Plant Sources Animal Sources By Distribution Channel Nutrition Stores Supermarkets Chemists Online Other Channels By End Use Dietary Supplements Food and Beverages Pharmaceuticals Other Uses By Geography North America (USA, Canada, Mexico) Europe (Germany, UK, France, Spain, Italy, Rest of Europe) Asia-Pacific (China, India, Japan, Australia, Vietnam, Rest of APAC) The Middle East and Africa (Middle East, Africa) South and Central America (Brazil, Argentina, Rest of SCA) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Protein Powder Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-06-2025
- Business
- Yahoo
Myelodysplastic Syndrome Competitive Landscape 2025: 262 Molecules in MDS Pipeline - A Peek into Future Therapeutics
Discover the competitive landscape of Myelodysplastic Syndrome (MDS) therapeutics. With 498,757 cases in 2024 and a slight increase by 2029, the report reveals a robust pipeline of 262 molecules and over 1,200 clinical trials. Uncover key market players, future catalysts, and strategic insights for effective market positioning. Dublin, June 05, 2025 (GLOBE NEWSWIRE) -- The "Myelodysplastic Syndrome: Competitive Landscape" report has been added to reports provides a data-driven overview of the current and future competitive landscape in Myelodysplastic Syndrome Therapeutics. The analyst epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Myelodysplastic Syndrome (MDS) infection in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. MDS is managed through a combination of supportive care, chemotherapy, and targeted therapies. The MDS pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87 assets in Phase II. Over the past decade, 1,229 clinical trials have been conducted in MDS. During the past decade, partnerships were most prevalent in North America and Europe. Report ScopeThe Myelodysplastic Syndrome Therapeutics: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease of the report include: Disease Landscape Disease Overview Epidemiology Overview Treatment Overview Marketed Products Assessment Breakdown by Mechanism of Action, Route of Administration Product Profiles with Sales Forecast Pricing and Reimbursement Assessment Annual Therapy Cost Time to Pricing and Time to Reimbursement Pipeline Assessment Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Late-to-mid-stage Pipeline Drugs Phase Transition Success Rate and Likelihood of Approval Clinical Trials Assessment Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status Enrolment Analytics, Site Analytics, Feasibility Analysis Deals Landscape Mergers, Acquisitions, and Strategic Alliances by Region Overview of Recent Deals Commercial Assessment Key Market Players Future Market Catalysts Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the Myelodysplastic Syndrome Therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Myelodysplastic Syndrome Therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market CatalystsFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Korea Herald
01-04-2025
- Business
- Korea Herald
Tencent Cloud Once Again Recognized as a Representative Vendor for Video Platform Services in the Gartner® Market Guide
Continuously leveraging AIGC technology to drive innovation in the cloud industry HONG KONG, April 1, 2025 /PRNewswire/ -- Tencent Cloud, the cloud business of global technology company Tencent, today announced that it is once again recognized as a Representative Vendor in the newly published Gartner® Market Guide for Video Platform Services report. Recently, it was also named as a Representative Vendor in the Gartner ® report titled "Competitive Landscape: Video Platform Services". This repeated recognition underscores Tencent Cloud's leadership in audio and video technology, its robust product portfolio, and its global service experience, solidifying its strong competitiveness in the global market. Tencent Cloud leverages its cutting-edge audio and video technology capabilities to help clients overcome their challenges, alongside its highly established and influential hybrid cloud deployment capabilities. Based on AI technologies such as large language models (LLMs) and digital image processing, Tencent Cloud enables the generation and enhancement of audio and video content, covering the entire production chain and multiple scenarios of audio and video content creation. Tencent Cloud's MPaaS offers a comprehensive suite of capabilities, including Media Processing Service (MPS), Cloud Streaming Services (CSS), Video on Demand (VOD), and Live Event Broadcasting (LEB), continuously driving digital transformation for industries worldwide. Deep Integration of AIGC Technology for Smarter Audio and Video Experiences With rapid advancements in large AI models, Tencent Cloud has actively integrated AIGC technologies—such as large language models (LLMs), audio and video generation, and multimodal understanding—into its media intelligence products. These innovations are now widely applied across scenarios like short drama globalization, education, live streaming, sports events, and entertainment. Tencent Cloud also integrates media intelligence capabilities into AI model training and generation workflows to enhance model performance. For example, in short drama globalization, Tencent Cloud's one-stop solution offers smart subtitle extraction, translation, original subtitle removal, translated subtitle embedding, voice cloning, and video synthesis to enable cost-effective global distribution. In educational, news, and speech-related video scenarios, Tencent Cloud leverages its Automatic Speech Recognition (ASR) and AI technologies to extract and summarize video content, allowing users to grasp key points without manual scrubbing. The solution also supports offline and live segmentation, auto-generating section summaries and keywords to help users quickly locate desired clips, improving efficiency. For live streaming, Tencent Cloud's media intelligence products provide real-time subtitles and translation in over 100 languages, breaking language barriers for global audiences—even allowing non-Chinese speakers to understand phrases such as"123, link up!" In sports, variety shows, and film/TV production, Tencent Cloud's Region-Of-Interest (ROI) intelligent recognition technology identifies visual content and key elements (e.g., faces, game characters, hosts) in real time, transmitting region-of-interest (ROI) data alongside encoded video to playback devices. This enables precise highlight clipping, smart anti-blocking for bullet chats, background blurring, and adaptive vertical cropping of horizontal videos for multi-device compatibility. Notably, Tencent Cloud's audio and video expertise also enhances large model training and generation. During the data cleaning phase of model training, the quality of training data directly affects the clarity and stability of the generated videos. Tencent Cloud's media quality inspection capabilities can automatically remove training materials with format errors or image quality defects, improving the overall quality of training videos. In video generation, outputting high-resolution and high-frame-rate video content has long faced technical challenges such as high computational power consumption and decreased model stability. Tencent Cloud's MPS (Media Processing Service) image quality enhancement capability, based on an improved Stable Diffusion architecture, optimizes the performance of distillation algorithms. It supports enhancing videos from 480P@30fps to 4K@120fps, significantly reducing the cost of generating ultra-high-definition videos while improving their clarity and stability. Currently, this capability has been implemented in several large model generation products, providing stronger technical support for AI content creation and helping various enterprises optimize video content efficiently. Continuous Innovation to Drive Global Digital Transformation Beyond AIGC, Tencent Cloud pushes the boundaries of audio and video technology, excelling in encoding, quality enhancement, and media inspection. It also prioritizes open media processing frameworks and industry collaboration. Tencent Cloud's MPS possesses leading encoding capabilities in the audio and video industry. It can save over 50% of the bitrate without compromising quality, significantly reducing operational costs for enterprises. Its mainstream encoding formats support the most comprehensive standards, including H.264/H.265/H.266/VP9/AV1, as well as the Chinese standards AVS2/AVS3. In the MSU World Video Coding Contest held at Moscow State University in 2024, Tencent's encoder took first place in all 15 indicators, once again achieving the best performance overall. Additionally, it supports the most comprehensive audio and video encoding standards, including VP8, H.264, VP9, H.265, AV1, AVS3, and H.266. Audio and video quality is one of the industry's major concerns. In this regard, for needs such as upgrading old video sources and enhancing image quality, MPS, based on the DiT (Diffusion Transformer) model that combines the advantages of diffusion models and Transformer architectures, provides over ten enhancement capabilities, including detail enhancement, color enhancement, SDR to HDR conversion, super-resolution, intelligent frame interpolation, and more. This can effectively help enterprises and users address various audio and video quality issues and bring a brand-new audiovisual experience. In addition to its leading technology research and development capabilities, Tencent Cloud has actively participated in the development of the H.266/VVC standard, becoming the world's first cloud provider to support H.266/VVC. Tencent Cloud holds key positions in the standardization organization, including as the joint chief editor and co-chair of the H.266/VVC standard, and is a significant technical contributor. Moreover, Tencent Cloud is the only founding member of AV1 in China and actively participates in the development of the AV2 standard, as well as the engineering of the H.267 standard. MPS collaborates with overseas ecosystem partners in areas such as audio and video processing and transmission. It supports technologies like Dolby Atmos, Dolby Vision, Nielsen, Nagra digital watermarks, and transmission standards such as SRT, SMPTE2022-07, SMPTE ST2110 with JPEG-XS, and NDI. This ensures that audio and video can be transmitted with low latency, stability, and smoothness. The Tencent Cloud audio and video team actively leads or participates in the development of many open-source audio and video projects such as SRS, SRT, VLC, fostering a mutually beneficial relationship between the cloud and the open-source community. Empowering Global Industries Powered by globally leading technology, Tencent Cloud Media Processing Service (MPS) offers a comprehensive, one-stop solution tailored for industries such as M&E and e-commerce, accelerating digital transformation across global markets. Through the continuous accumulation of technology and experience, Tencent Cloud has established close partnerships and provides stable technical support to overseas enterprises in the Asia-Pacific, Middle East, and North Africa regions, including Japan's karaoke app Pokekara, Singapore's streaming platform BeLive, Thailand's digital content platform Ookbee, and Pakistan's network TV service ARY ZAP. By these collaborations, Tencent Cloud expands its global footprint and provide a digital support and business innovation path for enterprise internationalization. Looking ahead, as AI and other technologies evolve, Tencent Cloud will persist in constructing an international business landscape from a global perspective. Leveraging its deep accumulation in the audio and video domain, Tencent Cloud will continue to increase its technological investment in audio and video, exploring innovative applications and business models to deliver superior, efficient, and personalized services that fuel high-quality growth across industries. Gartner, Market Guide for Video Platform Services, 19 March 2025 Gartner, Competitive Landscape: Video Platform Services, 18 December 2024 Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner ' s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved. About Tencent Cloud: Tencent Cloud, one of the world's leading cloud companies, is committed to creating innovative solutions to resolve real-world issues and enabling digital transformation for smart industries. Through our extensive global infrastructure, Tencent Cloud provides businesses across the globe with stable and secure industry-leading cloud products and services, leveraging technological advancements such as cloud computing, Big Data analytics, AI, IoT, and network security. It is our constant mission to meet the needs of industries across the board, including the fields of gaming, media and entertainment, finance, healthcare, property, retail, travel, and transportation.
Globe and Mail
12-03-2025
- Business
- Globe and Mail
Gupshup Earns Top Analyst Recognitions and Awards For Innovation in Conversational AI and Ready AI Agents
MUMBAI, India and SAN FRANCISCO , March 12, 2025 /CNW/ -- Gupshup, the world's leading Conversational AI platform today announced that it has been recognized by multiple esteemed analyst firms for its outstanding AI capabilities and market leadership in the evolving Conversational AI landscape. These accolades underscore Gupshup's position as a trailblazer in the space, driven by advancements in Generative AI (GenAI) and AI Agents. The company has been profiled in Gartner's Competitive Landscape for Conversational Solutions, named an 'Established Leader' in Juniper Research's Conversational AI Leaderboard, and recognized as a " Major Player " in the IDC MarketScape Worldwide Communications Platform as a Service Vendor Assessment report for its AI Agent offerings. In Gartner's Competitive Landscape for Conversational Solutions, Gupshup has been recognized among a select group of players, with specific mention of its Agentic AI capabilities across both text and voice interfaces. The report highlights how the conversational solutions market has transformed significantly with the advent of Generative AI, noting that technology and service providers must adapt their product strategies and positioning to incorporate AI agent development, GenAI security, engineering, and governance. Commenting on these recognitions, Beerud Sheth, Founder and CEO of Gupshup said, "Our Conversational AI Agents deliver deep industry-specific knowledge with the speed businesses demand. They process customer history and execute workflows while maintaining relevance—enabling enterprises to handle interactions at scale without sacrificing the human connection. By leveraging optimal foundational LLMs, we help companies rapidly implement AI solutions that drive measurable growth." Further solidifying its position, Gupshup has been named as an 'Established Leader' in Juniper Research's Conversational AI Leaderboard. Gupshup achieved the highest score for its conversational AI service products and offerings, particularly excelling in product positioning, innovation in the conversational AI market, and future prospects. Gupshup's portfolio of pre-built AI Agents for industry-specific use cases enable businesses to deploy AI-powered conversational agents seamlessly across messaging channels, reinforcing Gupshup's leadership in conversational AI for customer engagement. Additionally, Gupshup has been acknowledged as a 'Major Player' in the IDC MarketScape Worldwide Communications Platform as a Service (CPaaS) Vendor Assessment. The report underscores the critical role of AI-driven engagement in driving double-digit growth in 2025. This recognition validates the company's cutting-edge Agentic AI capabilities, which are empowering enterprises to deploy sophisticated AI-powered experiences across multiple channels. Beyond these analyst recognitions, Gupshup has also received multiple prestigious awards, including: 'Best Innovation Leveraging GenAI/ML' at the recently concluded AWS AI Conclave Gold Winner for 'Best Conversational Commerce Solution' at the Future Digital Awards Platinum Winner for 'Mobile Messaging Innovation' at the Future Digital Awards Inderpal Mumick , EVP of Telecom Business at Gupshup and CEO of Dotgo (a company acquired by Gupshup), was named Platinum Winner for Mover & Shaker in Telco at the Future Digital Awards. With these significant recognitions and milestones, Gupshup continues to shape the future of Conversational AI, empowering businesses worldwide with cutting-edge AI-driven engagement solutions.
